Publications by authors named "Shamik Parikh"

Claim this Profile
L
Long-term safety and efficacy outcomes of the Acellular Tissue Engineered Vessel (ATEV) in extremity arterial trauma repair.
Michael A Curi, Ernest E Moore, Nicholas Namias, Rishi Kundi, Ying Wei Lum, Shamik Parikh

J Vasc Surg Cases Innov Tech· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioengineered human blood vessels to treat hospital-acquired vascular complications.
YingWei Lum, Ernest E Moore, Rishi Kundi, Jonathan Morrison, Jamie T Shores, Shamik Parikh

J Vasc Surg Cases Innov Tech· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short-term performance of Symvess (acellular tissue engineered vessel-tyod) compared to external control data for autologous vein in treatment of extremity arterial injury.
Ravi R Rajani, Fulton F Velez, Tyler Knight, Laura Kauffman, Luigi Pascarella, Shamik Parikh

Trauma Surg Acute Care Open· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrections and Clarifications to Address Concerns About Reporting of Studies of Bioengineered Arteries for Repair of Extremity Vascular Injuries.
Shamik J Parikh, Laura E Niklason

JAMA Surg· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Safety and Efficacy of Humacyte Acellular Tissue-Engineered Vessel in a Real-World Combat Setting: A Retrospective Observational Multicenter Study.
Shamik Parikh, Oleksandr Sokolov, Vasyl Shaprynskyi, Oleh Skupyy, Oleksandr Stanko

Mil Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioengineered Human Arteries for the Repair of Vascular Injuries.
Ernest E Moore, Michael Curi, Nicholas Namias, Rishi Kundi, Ying Wei Lum, Shamik J Parikh

JAMA Surg· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case of ST-Elevation Myocardial Infarction in a 32-Year-Old Male Receiving Bleomycin, Etoposide, and Cisplatin Chemotherapy for Embryonal Carcinoma.
Emmanuel Bassil, Harjinder Singh, Omair Ahmed, Shamik Parikh

Cureus· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatitis, panniculitis and polyarthralgia syndrome: A rare complication of pancreatic pathology.
Harjinder Singh, Parth Patel, Shamik Parikh, Hassan Zreik, Neil Caliman

Radiol Case Rep· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade.
Michael A Weber, Traci A Mansfield, Federica Alessi, Nayyar Iqbal, Shamik Parikh

Blood Press· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies.
Paola Fioretto, Traci A Mansfield, Agata Ptaszynska, Yshai Yavin, Eva Johnsson, Shamik Parikh

Drugs Aging· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
Donald Elliott Kohan, Paola Fioretto, Kristina Johnsson, Shamik Parikh, Agata Ptaszynska

J Nephrol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Kristina Johnsson, Eva Johnsson, Traci A Mansfield, Yshai Yavin, Agata Ptaszynska, Shamik J Parikh

Postgrad Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Michael A Weber, Traci A Mansfield, Valerie A Cain, Nayyar Iqbal, Shamik Parikh

Lancet Diabetes Endocrinol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis.
Yshai Yavin, Traci A Mansfield, Agata Ptaszynska, Kristina Johnsson, Shamik Parikh

Diabetes Ther· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability.
Tjerk W A de Bruin, Stots Reele, Jennifer E Hamer-Maansson, Shamik Parikh, Weifeng Tang

Clin Pharmacol Drug Dev· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
Serge A Jabbour, Elise Hardy, Jennifer Sugg, Shamik Parikh,

Diabetes Care· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.
William T Cefalu, Lawrence A Leiter, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh

Diabetes Care· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Stephan Matthaei, Keith Bowering, Katja Rohwedder, Anke Grohl, Shamik Parikh

Diabetes Care· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
Agata Ptaszynska, Kristina M Johnsson, Shamik J Parikh, Tjerk W A de Bruin, Anne Marie Apanovitch

Drug Saf· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension.
Lawrence A Leiter, William T Cefalu, Tjerk W A de Bruin, Ingrid Gause-Nilsson, Jennifer Sugg, Shamik J Parikh

J Am Geriatr Soc· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.
Krzysztof Strojek, Kun-Ho Yoon, Veronika Hruba, Jennifer Sugg, Anna Maria Langkilde, Shamik Parikh

Diabetes Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urinary tract infections in patients with diabetes treated with dapagliflozin.
Kristina M Johnsson, Agata Ptaszynska, Bridget Schmitz, Jennifer Sugg, Shamik J Parikh

J Diabetes Complications· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
Suzanne Geerlings, Vivian Fonseca, David Castro-Diaz, James List, Shamik Parikh

Diabetes Res Clin Pract· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin on cardiovascular risk factors.
Agata Ptaszynska, Elise Hardy, Eva Johnsson, Shamik Parikh, James List

Postgrad Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis